Regeneron to Report Q3 Earnings: What’s in the Offing?
ZacksInvestors’ focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.
Investors’ focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports third-quarter 2024 results.